Contract Manufacturing Agreement by and between Amphastar Nanjing Pharmaceuticals, Inc. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd, dated April 19, 2022
Exhibit 10.1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE
THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED
CONTRACT MANUFACTURING AGREEMENT
委托生产协议
This Contract Manufacturing Agreement (this “Agreement”) is entered into by and between the following parties on April 19, 2022 (the “Effective Date”):
本委托生产协议(“本协议”)由以下双方于 2022 年 4 月19日(“生效日”)签订:
(1) Nanjing HanXin Pharmaceutical Technology Co., Ltd., a limited liability company duly incorporated and validly existing under the laws of PRC, with the Unified Social Credit Code: ****************** (the “Customer”); and
(1) | 南京汉欣医药科技有限公司, 一家根据中国法律注册并存续的有限责任公司,社会统一信用代码为:******************(“委托方”);及 |
(2) Amphastar Nanjing Pharmaceuticals, Inc., a limited liability company duly incorporated and validly existing under the laws of PRC, with the unified social credit code: ****************** (“ANP”).
(2) 美药星(南京)制药有限公司,一家根据中国法律注册并存续的有限责任公司,社会统一信用代码为:******************(“ANP”)。
ANP and the Customer are sometimes referred to herein collectively as the “Parties” and individually as a “Party”.
本协议项下ANP和委托方合称为“双方”,单独称为“一方”。
Whereas, the Customer intends to engage ANP to manufacture certain active pharmaceutical ingredients and/or finished pharmaceutical product based on specifications and formula provided by the Customer, and ANP intends to accept such engagement.
鉴于,委托方有意委托ANP依照其质量标准及规程进行相关活性药物成分和/或成品药的生产,ANP有意接受该等委托。
Therefore, based on the principle of good faith, the Parties hereby agree as follows:
因此,双方基于诚实信用原则达成如下约定:
1. | General |
1. | 总则 |
1.1 | Headings or titles of this Agreement are used solely for convenience and shall be given no effect in the construction or interpretation of this Agreement. |
1.1 | 本协议标题仅为方便查阅而设,不影响对本协议的解读或解释。 |
1.2 | Additional agreements necessary to effectuate this Agreement, including but not limited to, a Quality Agreement, may be executed between the Parties. In the event of conflicting terms, the terms of this Agreement shall prevail. |
1.2 | 双方可以签署为实现本协议所必需的附属协议,包括但不限于质量协议。如有冲突,则以本协议的约定为准。 |
1.3 | When used in this Agreement, the following terms shall have the meanings set forth in this section: |
1.3 | 本协议中使用的术语含义解释如下: |
(a) | “Affiliate” means any person or entity which controls, is controlled by or is under the common control of a Party. As used in this Agreement, “control” means (i) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, or (ii) in the case of non-corporate entities, the direct or indirect power to manage, direct or cause the direction of the management and policies of the non-corporate entity. |
(a) | 关联方:指控制一方、受一方控制或与一方受共同控制的任何个人或实体。在本协议中,“控制”指(i)在公司实体中,直接或间接持有该实体不少于百分之五十(50%)的有权选举董事的投票权的股权或股份;或(ii)在非公司实体中,拥有直接或间接参与该实体的管理、决定或指导该实体管理政策的方向的权力。 |
(b) | “Applicable Law” means all ordinances, rules, regulations, laws, and requirements of any authority applicable to the Manufacture, supply and/or use of the Product, as amended from time-to-time, including cGMP. |
2
(b) | 适用的法律:指不断修订的适用于产品的制造、供应和/或使用的任何监管机构的所有法令、规则、法规、法律和要求,包括 cGMP。 |
(c) | “Confidential Information” means technical and business information relating to inventions, proprietary ideas and/or patentable ideas, patent applications, background intellectual property, techniques, scientific knowledge, know-how processes, existing and/or contemplated products and services, software, biological material, schematics, research and development, production, costs, profit and margin information, finances and financial projections, customers, clients, licensees, marketing, and current or future business plans and models, regardless of whether such information is designated as “Confidential Information” at the time of disclosure. The term “Confidential Information” does not include such information which: |
(i) | is or becomes generally available to the public, other than through the receiving party’s disclosure, |
(ii) | was within the receiving party’s possession prior to it being furnished by or on behalf of the disclosing party, provided that receiving party’s source had no obligation of confidentiality to the disclosing party, |
(iii) | becomes available to the receiving party on a non-confidential basis from an information provider other than the disclosing party, provided that the information provider did not have a duty of confidentiality to the disclosing party, or |
(iv) | is or becomes independently developed by an employee of the receiving party without access to the Confidential Information and without violating any of the receiving party’s obligations under this Agreement, as can be demonstrated by the receiving party’s written records. |
(c) | 保密信息:指与发明、专有思想和/或可转化为专利思想、专利申请、底层知识产权、技术、科学知识、专有技术流程、现有的和/或预期的产品和服务、软件、生物材料、示意图、研究和开发、生产、成本及利润信息、财务和财务预测、顾客、客户、被许可方、市场销售以及当前或未来的商业计划和模式有关的技术和商业信息,无论该等信息在披露时是否被指定为“保密信息”。“保密信息”不包括以下信息: |
(i) | 在接收方披露前,已是公开或公众普遍可用的, |
(ii) | 在披露方提供或代表披露方提供信息之前,接收方已拥有的信息,前提是接收方的信息来源对披露方没有保密义务, |
(iii) | 接收方在非保密的基础上已从披露方以外的信息提供方获得的信息,前提是信息提供方对披露方没有保密义务,或 |
3
(iv) | 接收方的员工在未接触保密信息且未违反接收方在本协议项下的任何义务的情况下,已独立开发获得的信息,且有接收方的书面记录证明。 |
(d) | “Contract Year” means each consecutive twelve (12) month period during the Term, the first of which shall commence on the Launch Date and shall end on the first anniversary thereof. |
(d) | 合同年:指协议期限内每一连续的十二(12)个月,第一个合同年从上市日期开始至一周年后结束。 |
(e) | (e)“Finished Product” means for each Product, packaged with primary packaging and/or secondary packaging, in a commercially presented outer carton labelled for the purpose of sale or use in the Territory. |
(e) | “成品”:指就每项产品而言,用商业展示的贴有标签外纸箱进行初级包装和/或次级包装,以用于在区域内销售或使用。 |
(f) | “Force Majeure” means an event beyond the reasonable control of a Party including but not limited to, a breakdown of machinery or equipment, fire, flood, sabotage, shipwreck, embargo, strike, explosion, labor trouble, pandemic and related restrictions, accident, riot, act of governmental authority (including without limitation, acts relating to raw material or product allocation, and government drug files), acts of God, acts of war and delays or failures in obtaining materials, supplies, equipment or transportation. |
(f) | 不可抗力:指超出一方合理控制范围的事件,包括但不限于机器或设备损毁、火灾、洪水、破坏、海难、禁运、罢工、爆炸、罢工、流行病和相关限制、事故、暴乱,政府当局的行为(包括但不限于与原材料或产品分配有关的行为,以及政府药事文件)、天灾、战争行为以及材料、供应品、设备或运输的延误或损坏。 |
(g) | “NMPA” means the National Medical Products Administration and any successor agency having substantially the same functions. |
(g) | NMPA:指国家药品监督管理局,或具备相同职能的任一下属机构。 |
(h) | “Launch Date” means, with respect to each Product under this Agreement, the date of the first commercial sale of such Product by the Customer or its Affiliates or their respective designees in the Territory. |
(h) | 上市日期:指就本协议项下的某一产品,委托方或其关联方或各自的指定人员在区域内首次商业化销售本协议中该产品的日期。 |
4
(i) | “Manufacture” and “Manufacturing” means any steps, processes and activities necessary to produce the Product, including without limitation, the manufacturing, processing, bulk packaging and labeling, quality control testing, release and storage of the Product. |
(i) | 生产:指产品生产所需的任何步骤、流程及操作,包括但不限于产品的制造、加工、批量包装和贴签、质量控制测试、放行和储存。 |
(j) | “Marketing Authorization” means, with respect to each Product, the regulatory filing made by or on behalf of the Customer with, and approved by, the NMPA, that allows the Customer to market products comprised of or containing such Product in the Territory, including without limitation, any supplements or amendments thereto. |
(j) | 上市许可:就某一产品而言,指由委托方或委托方代表向NMPA提交并经NMPA批准的监管文件,该文件允许委托方在区域内销售由该产品组成或含有该产品的药品,包括但不限于针对该等文件内容的任何补充和修改。 |
(k) | “PRC” means the People’s Republic of China, but solely for the purposes of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and the islands of Taiwan. |
(k) | 中国:指中华人民共和国,仅为本协议之目的,不包括香港特别行政区、澳门特别行政区和台湾地区。 |
(l) | “Product” means the active pharmaceutical ingredients or finished pharmaceutical product listed in Appendix A hereof. |
(l) | 产品:指本协议附录A中列明的活性药物成分和成品药。 |
(m) | “Regulatory Dossiers” means all registration, permits, licenses, authorizations, approvals, presentations, notifications or filings (together with all applications therefore), which are filed with or granted by the governing health authority of any country, and which are required to develop, make, use, or sell the Product. |
(m) | 监管档案:指产品的研发、生产、销售及使用所需的,向任一国家的卫生政府部门提交的或由任一国家的卫生政府部门授权的所有注册、许可、执照、授权、批准、介绍、通知或备案文件(及其全部申请材料)。 |
5
(n) | “Specifications” means the specifications set fort in Appendix B hereof, as such specifications may be adjusted from time to time by mutual written consent of the Parties. |
(n) | 质量标准:指本协议附录B列明的质量标准,可经由双方共同书面同意不时调整。 |
(o) | “Term” means the period during which this Agreement is in effect as set forth in Section 13. |
(o) | 协议期限:指本协议第13条所约定的本协议的生效期限。 |
(p) | “Territory” means the PRC. No other territory rights are granted or applicable to this Agreement. The Customer is specifically prohibited from making any use of the Product outside of the PRC. |
(p) | 区域:指中国。其他地区规定的权利不适用于本协议。委托方禁止在中国境外使用产品。 |
(q) | “Contract Price” means, with respect to each Product, the Selling Price for each Product as provided in Appendix A, as such selling price may be adjusted based on the terms and conditions of this Agreement. |
(q) | 合同价格:指附录A列明的每项产品的销售价格,可根据本协议的条款和条件进行调整。 |
2. | The Customer’s Rights and Obligations |
2. | 委托方权利义务 |
2.1 | At least thirty (30) days prior to the Launch Date, and the first day of each calendar quarter after such Launch Date, the Customer shall provide ANP with a good faith estimate of the Customer’s projected quantity requirements of such Product for delivery during each of the following four (4) calendar quarters (each such estimate being a “Forecast”). The Forecast corresponding to the first two (2) calendar quarters shall be legally binding on the Customer and shall not be amended without prior written consent of ANP. ANP will prepare and deliver a manufacture plan (“Manufacture Plan”) to the Customer within thirty (30) business days after receipt of the Forecast provided by the Customer. The Customer shall confirm or raise objections (if any) within ten (10) business days after receipt of the Manufacture Plan. If the Customer fails to confirm or raise an objection within the aforementioned period, it shall be deemed that the Customer agrees to the Manufacture Plan formulated by ANP, and the Manufacture Plan of the first two (2) calendar quarters of the Manufacture Plan confirmed or deemed to be agreed by the Customer shall bind the Customer to purchase at least the amount of Product specified in the Manufacture Plan from ANP. |
2.1 | 于产品上市日期前至少三十(30)日,以及于上市日期后的每个日历季度的首日,委托方应向ANP提供关于委托方在随后四(4)个日历季度中每一(1)季度该等产品数量需求的 |
6
善意预估(该等预估称为“预测”)。前两(2)个日历季度对应预测对委托方具备法律约束力,未经ANP事先书面同意,不得变更。ANP在收悉委托方提供的预测后的 30 个工作日内制订生产计划(“生产计划”)并提供给委托方。委托方应当在收悉ANP生产计划后10日内进行确认,如存在异议的,应当于前述期限内提出。如委托方未能于前述期限内确认或提出异议的,视为委托方同意ANP制定的生产计划,委托方确认或视为同意的生产计划中前两(2)个日历季度的生产计划对委托方具备法律约束力,委托方有义务向ANP购买不低于前述生产计划约定数量的产品。 |
2.2 | The Customer shall issue purchase orders to ANP in accordance with the Manufacture Plan set forth in section 2.1. The purchase order shall specify the quantity, standard, expected delivery date and other matters mutually agreed by the Parties. The Parties hereby agree that the Customer shall provide ANP with a delivery period of no less than ninety (90) days. ANP shall confirm within ten (10) business days after receipt of the purchase order, and in the event that the purchase order does not conforms to this Agreement, or quantity of the Product is less than or exceeds the committed quantity agreed in the Manufacture Plan, ANP shall be entitled to reject such order. In the event that the Customer does not issue purchase orders for all of the committed quantity in any quarter, ANP may bill the Customer at the end of the quarter for the balance of the binding quantity for such calendar quarter and the Customer shall remit payment to ANP upon receipt of the invoice. |
2.2 | 委托方应根据本协议第2.1条约定的生产计划向ANP发出采购订单,采购订单中应明确委托生产药品的数量、规格、拟要求交付时间以及其他双方共同同意的事项。双方确认,委托方应为ANP提供至少九十(90)日的交货周期。ANP应当于收悉委托方采购订单10个工作日内进行确认,如委托方采购订单不符合本协议约定、低于或超出生产计划约定的数量,ANP有权拒绝。如果委托方于任一季度未能下达满足本协议约定的所有承诺需求的采购订单,ANP可在该季度末向委托方开具该季度承诺需求对应的费用发票,委托方应在收悉发票后支付相应款项。 |
2.3 | The Customer shall purchase from ANP the minimum quantities of the Product (the “Committed Purchase Quantities”) at the Contract Price in each calendar year as provided in the table set forth below. In the event that the Customer fails to meet the Committed Purchase Quantities in any given calendar year, the Customer shall pay ANP for the difference between the amount of the Committed Purchase Quantities and the actual amount purchased for the corresponding calendar year (such difference, the “Committed Purchase Difference”). ANP shall issue an invoice and the Customer shall pay the Committed Purchase Difference no later than thirty (30) days after the end of the |
7
corresponding calendar year. |
2.3 | 委托方应按合同价格在每个日历年度向ANP购买不低于如下表所示的最低数量的产品(“承诺采购数量”)。如果委托方在任何特定日历年度未能满足承诺采购数量,委托方应向ANP支付承诺采购数量金额与实际采购数量金额之间的差额(该等差额称为“承诺采购差额”)。ANP应不迟于相应日历年度结束后三十(30)日内就该等差额向委托方开具发票,且委托方应不迟于前述日期向ANP支付承诺采购差额。 |
Calendar Year 日历年度 | Committed Purchase Quantities (Units) 承诺采购数量(单位) | Contract Price (per Unit) 合同价格(每单位) |
2024 -2028 | To be agreed by both parties after the Launch Date | Selling Price as provided in Appendix A |
3. | ANP’s Rights and Obligations |
3. | ANP权利义务 |
3.1 | ANP shall deliver the Product to the Customer according to the requirements of the purchase orders confirmed by ANP, and FCA rules under International Rules for the Interpretation of Trade Terms 2020 (Incoterms 2020) shall apply to such delivery. The Parties hereby agree that ANP’s additional costs arising from such delivery (including but not limited to, costs for transportation, customs and late receipt of the Customer’s designated carrier) shall be borne by the Customer. |
3.1 | ANP应根据ANP确认的订单要求向委托方交付产品,产品交付方式依照《国际贸易术语解释通则(2020年版)》FCA术语规则。双方确认,ANP因产品交付产生的额外费用成本(包括但不限于运输费用、出口清关费用、委托方指定承运人逾期收货费用)应由委托方承担。 |
3.2 | ANP shall Manufacture and deliver the Product in conformance with the Applicable Law and regulations and Specifications. |
3.2 | ANP应依据适用法律、法规及质量标准的相关规定生产和交付产品。 |
3.3 | ANP shall make commercially reasonable efforts to ensure that it can supply the Customer with sufficient quantities of the Product pursuant to the Forecast. |
3.3 | ANP应尽合理商业努力以确保交付满足委托方预测数量的产品。 |
8
4. | Contract Price, Invoice and Payment |
4. | 合同价格、开票及结算 |
4.1 | ANP shall issue invoices within five (5) business days after shipment, unless the Parties determine that the Product does not conform to the Specifications, payment shall be due thirty (30) days after the date of an invoice from ANP. |
4.1 | ANP应在发货后五(5)个工作日内向委托方开具发票,除非经由双方确认产品不符合质量标准,委托方应在ANP开具发票后三十(30)日内完成付款。 |
4.2 | During the Term of this Agreement and not more than once during any twelve (12) month period, the Contract Price may be subject to an adjustment, provided that ANP provides the Customer with two (2) months prior written notice of such proposed Contract Price adjustment. |
4.2 | 于协议期限内,ANP可经提前两(2)个月向委托方发出书面通知调整合同价格,该等合同价格调整在每十二(12)个月内不得超过一(1)次。 |
4.3 | If ANP’s manufacturing costs rise due to increased costs (e.g., due to increased power or labor costs, increased standards on environmental protection), the Parties shall separately agree on the Contract Price change after the Customer’s verification of the increased costs using information supplied by ANP. During the negotiation of Contract Price change, ANP shall provide the relevant staff salary information, power cost invoices, environmental protection expenditure information, or other supporting materials. If the Customer adjusts the Specifications or relevant requirements unilaterally, or direct ANP to purchase designated raw materials and packaging materials, the Contract Price shall be adjusted accordingly. For the avoidance of doubt, the adjustment of the Contract Price under this section 4.3 shall not be subject to the advance notice and time limit set forth in section 4.2 hereof. |
4.3 | 如果ANP的生产成本因相关成本增加(例如因能耗、人工成本增加、环境保护标准提高等原因增加),双方应在委托方核实ANP提供的成本增加的相关信息后另行商定合同价格的变更。在双方合同价格变更沟通期间,ANP应提供相关人员工资信息、电费发票、环保支出信息等配套材料。如果委托方要求单方变更质量标准或产品要求,或向ANP指定原材料、包材的采购,合同价格需相应调整。为免疑义,本第4.3条合同价格调整不受限于本协议第4.2条约定的提前通知期限及次数限制。 |
9
5. | Quality Agreement |
5. | 质量协议 |
5.1 | The Parties will separately enter into a Quality Agreement setting forth in detail the certain rights and responsibilities divided among themselves that relate to the quality of the Product. |
5.1 | 双方将另行签订质量协议以详细约定彼此之间与产品质量相关的权利义务的划分。 |
6. | Supply of the Product |
6. | 产品供应 |
6.1 | ANP shall promptly notify the Customer of any circumstances that result or are likely to result in any failure or delay in the supply or delivery of any Product in writing. If the Parties have a good faith belief, after mutual communication, that such circumstances may result in the failure or delay in the supply or delivery of such Product for more than ninety (90) days from the date of ANP’s written notice, the Customer shall have the right to terminate such delivery after the full payment of costs and expenses of such Product to ANP. |
6.1 | ANP应将任何导致或可能导致任何产品交付失败或延误的问题及时书面告知委托方,双方经沟通后认为该等情形将导致ANP无法于ANP发出书面通知之日起九十(90)日内完成产品交付的,委托方有权在支付ANP该等产品成本及费用的情况下终止该等产品的该等交付。 |
7. | Inspection of the Product |
7. | 产品检验 |
7.1 | All Product received by the Customer will be subject to inspection and testing by the Customer, in accordance with the Customer’s quality assurance program, within a period of thirty (30) days from the date of receipt of such Product (“Inspection Period”). The Customer will notify ANP if the results of any inspection or testing indicate that the Product does not conform to the applicable Specifications or the other requirements under this Agreement. ANP will have ten (10) business days to respond to the Customer’s notice of non-conformance. Disputes between the Parties not resolved within ten (10) business days will be resolved by an independent laboratory selected by mutual consent of the Parties. A laboratory will be appointed not later than fifteen (15) business days after the expiry of the ten (10) business day period. If the laboratory finds the Product to be nonconforming, then at ANP’s sole discretion, ANP will (a) promptly deliver, at ANP’s sole expense, the replacement Product that conforms to the requirements under this Agreement, or (b) |
10
refund or credit to the Customer all payments made by the Customer with respect of such nonconforming shipment. The Customer will, at the ANP’s sole discretion, return or destroy the nonconforming Product at ANP’s sole expense, including without limitation transportation and handling costs. |
7.1 | 收悉产品的三十(30)天内(“检验期”),委托方将根据其质量保证程序对产品质量进行检验与测试。若检验或测试结果显示产品不符合质量标准或本协议的其他要求,委托方将通知ANP。ANP应在十(10)个工作日内进行回复。若在十(10)个工作日内双方未达成一致,争议将通过经双方一致认可的独立实验室解决。双方将在上述十(10)个工作日期限届满后的十五(15)个工作日内就独立实验室的选择达成一致。若实验室检验结果仍不合格,ANP应做出下列选择:(a)立即进行产品更换且费用自理,更换的产品应满足本协议要求;(b)将委托方就此类不合格产品支付的所有款项退还给委托方或调整为对委托方的应付款。经由ANP决定,委托方将退回或销毁不合格产品,相关费用由ANP承担,包括但不限于运输和处理费用。 |
8. | Regulatory Matters |
8. | 监管条款 |
8.1 | The Customer is responsible for filing and obtaining any Marketing Authorization that is required for the marketing and sale of the Product supplied by ANP; however, ANP shall reasonably cooperate with the Customer in such activities. Each Party shall notify the other Party promptly upon becoming aware of any (a) defective, adulterated or misbranded Product or of any information which may suggest that any Product is or may be defective, adulterated or misbranded, or (b) the Product which fails to meet the Specifications, the requirements of the applicable Marketing Authorization and Applicable Law. ANP will make reasonable commercial efforts to assist the Customer in investigating adverse experiences and customer complaints relating to the Product. ANP agrees to notify the Customer promptly of any inspections by the NMPA or any other authority which pertain to or have any quality implications for the Product. ANP will provide the Customer with any necessary authorization to allow the NMPA or any other authority to inspect, audit and review the facilities at which the Product is Manufactured. ANP will retain originals of all batch documentation, any and all other records or documentation generated by ANP in connection with the manufacturing and testing of the Product under the terms of this Agreement, and all records which may be reasonably necessary to assist the Customer in the event of the Product Recall or adverse drug event, for the longer of (a) two (2) years after the expiration date of the batch |
11
of the Product to which they pertain or (b) the period required by Applicable Law. The costs and expenses incurred by ANP in cooperating with the Customer in investigations, inspections and obtaining relevant Marketing Authorization set forth in this section 8.1 shall be borne by the Customer. |
8.1 | 委托方负责申请和获得ANP所生产产品的上市许可,ANP应与委托方充分合作以获得该等许可。一方发现任何问题,应立即通知另一方,包括:(1) 产品有缺陷、掺货、贴错标签或任何可能表明产品存在或可能存在缺陷、假货或贴错标签的情形;(2) 产品不符合质量标准、相关上市许可及适用法律要求的情形。ANP将尽合理商业努力协助委托方调查与产品相关的不良体验和投诉问题。ANP应将NMPA或任何其他机构进行的与产品有关或能反应产品质量的所有检查通知给委托方。ANP将向委托方提供必要范围的授权,以允许NMPA和其他机构对ANP产品设施进行必要检查、审计和审查。ANP将保留所有与产品相关的必要的审批记录的原件,所有与本协议项下产品生产或测试有关的记录或文件,以及所有为协助委托方完成产品召回或产品不良反应调查而合理需要的记录文件,该等文件的保留时间应按(a) 每批产品到期日后两(2)年或(b) 适用法律规定的时限(以较长者为准)。本8.1条项下ANP因配合委托方相关调查、检查、获得相关上市许可所产生的费用应由委托方承担。 |
9. | Facility Qualification |
9. | 设施资质 |
9.1 | ANP shall, take all commercially reasonable actions to qualify (and thereafter to maintain qualification of) the facility at which ANP Manufactures the Product, as required under Applicable Law, to enable the Customer to obtain and maintain all applicable Regulatory Dossiers for the Customer’s Finished Product. ANP will permit the Customer and its agents, at the Customer’s expense, during normal business hours and upon reasonable prior notice to ANP, and no more than once per year, to inspect the Facility where the Product is Manufactured, handled, stored, or tested, as well as all batch records (without making any copies) and processes relating to the Manufacture, storage, handling, or testing of the Product and all Manufacturing, handling, storage, and test records regarding the Product. ANP will respond to any non-conformances noted by the Customer, within thirty (30) business days of the written notification of such non-conformances, by submitting to the Customer a written report stating causes and corrective actions planned, and providing a timetable for the correction. Notwithstanding the foregoing, all data relating to the process which is contained in the closed part of the DMF will remain confidential and Customer |
12
has no right to review or receive such information during any inspection, audit, or review described in this Section 9.1. |
9.1 | ANP应根据相关法律要求,采取一切商业上合理的措施使其生产产品的设施获得(并维持)相应资质,以确保委托方能够获得并维持所有与药品成品有关的监管档案。ANP应允许委托方及其代理商在事先通知的情况下,在正常工作时间内对与产品生产、处理、贮存或测试相关的设施、或与产品生产、贮存、处理或测试相关的批次记录(不可复制副本)和工艺流程、以及产品的所有生产、处理、贮存或测试记录进行每年不超过一(1)次的检查,相关费用由委托方承担。ANP应在收到委托方的不合格书面通知后三十(30)个工作日内向委托方进行回复,通过纸质报告说明不合格原因与相应改正措施,并提供改正的具体时间安排。尽管有上述约定,就药品主文件中已经封闭的部分中与工艺相关的全部数据应保密,且委托方无权在第9.1条约定的任何检查、审计或审查过程中要求审阅或获取该等信息。 |
10. | Manufacturing Practices |
10. | 生产操作 |
10.1 | ANP shall Manufacture the Product in conformance with the Specifications and the Marketing Authorization. ANP shall provide the Customer with such information, including analytical and manufacturing documentation, requested by Customer regarding quality control of Product supplied hereunder. ANP will solely be responsible for keeping proper records and documentation of the manufacturing and testing of the Product, intermediates, and starting materials, including batch records, testing records, laboratory notebooks, equipment usage, starting material batch numbers, and certifications. ANP will be responsible for investigating any test results or in-process testing of the Product that does not conform with the Specification. ANP will conduct such laboratory investigation, which must be approved by ANP’s quality unit, and ANP will promptly notify the Customer of any adverse reactions or other safety or toxicity problems known to or reasonably suspected by ANP regarding the Product or its use. ANP will promptly notify Customer of the results of any regulatory inspection, comments, responses or notices received from the NMPA or other applicable regulatory authorities, which relate to or may impact the Manufacture and supply of the Product to the Customer. |
13
11. | Recall |
11. | 召回 |
11.1 | During the Term, if either Party believes that it may be necessary to conduct a recall, field correction, market withdrawal, stock recovery, or other similar actions with respect to any Customer’s Finished Product containing the Product (a “Recall”), ANP and the Customer shall consult with each other as to how best to proceed. The Parties hereby agree that the final decision as to any Recall of any such Customer’s Finished Product shall be made by the Customer; provided, however, that ANP will not be prohibited hereunder from taking any action that is required by Applicable Law. The Customer shall be in charge of the Recall and establish a product recall system and recall management procedures, and ANP shall cooperate with the Customer as required by Applicable Law. In the event of a Recall, the Parties shall jointly find out and confirm reasons for the Recall, and except for reasonable costs borne by ANP if a Recall incurred solely attribute to it, the Customer shall bear all costs incurred thereby. |
12. | Certificate of Analysis |
12. | 检验报告 |
14
13. | Term, Amendment and Termination |
13. | 协议期限、变更、解除或终止 |
(a) | The Terminated Party breaches this Agreement and (i) does not rectify its default within thirty (30) days on the date of receiving written notice from the Terminating Party requiring for rectification; or (ii) there is no realistic possibility to rectify such default; or (iii) such default has resulted in the inability to achieve the purpose of this Agreement; |
(b) | The Terminated Party suffers a Force Majeure event which makes it impossible to achieve the purpose of this Agreement; |
(c) | The Terminated Party expresses clearly or by behavior that it will not perform its obligations hereunder, or delays the performance of its obligations and has not fully performed the obligations after being notified; |
(d) | The Terminated Party loses the ability to perform its obligations hereunder, including but not limited to, entering bankruptcy proceedings, liquidation proceedings, being dissolved, being winding up, being revoked, or losing appropriate qualifications. |
(a) | 被解除方违反本协议约定且(i) 在收悉解除方书面通知要求其纠正违约行为之日起三 |
15
十(30)日内未纠正其违约行为的;或(ii) 实际上已不存在纠正违约行为的可能或(iii) 存在违约行为导致不能实现协议目的; |
(b) | 被解除方遭遇不可抗力且不可抗力致使不能实现协议目的; |
(c) | 被解除方明确表示或以行为表明不履行本协议义务,或者迟延履行本协议义务且经催告后仍未全面履行的; |
(d) | 被解除方丧失协议履行能力,包括但不限于,进入破产程序、清算程序、被解散、被注销、被吊销、丧失相应资质。 |
16
14. | Intellectual Property Rights |
14. | 知识产权 |
17
15. | Warranties |
15. | 保证 |
18
19
16. | Indemnities |
16. | 赔偿 |
20
21
17. | Confidential Information |
17. | 保密信息 |
22
23
24
18. | Force Majeure |
18. | 不可抗力 |
19. | Notices |
19. | 通知 |
If to the Customer: | Nanjing HanXin Pharmaceutical Technology Co., Ltd. Address: Building C5, No.9 Weidi Road, Xianlin University Town, Qixia District, Nanjing, Jiangsu, China Attn: Bob Bao Post Code: 210033 Amphastar Nanjing Pharmaceuticals, Inc. Address: No. 5 Xinghe Road, Nanjing Economic and Technological Development Zone, Jiangsu, China Attn: Perky Qiu Post Code: 210038 |
25
If to ANP: |
委托方:南京汉欣医药科技有限公司
地址:中国江苏省南京市栖霞区仙林大学城纬地路9号C5栋
联系人:鲍海涛
邮箱:2110033
ANP:美药星(南京)制药有限公司
地址:中国江苏省南京经济技术开发区兴和路5号
联系人:邱银华
邮编:210038
26
22. | Assignment |
22. | 转让 |
27
23. | Severability |
23. | 可分割性 |
24. | Entire Agreement |
24. | 完整协议 |
25. | Waiver |
25. | 弃权 |
28
26. | Publicity |
26. | 公开发布 |
27. | Appendices |
27. | 附录 |
28. | Limitation of Liability |
28. | 责任限制 |
29
29. | Counterparts and Language |
29. | 副本和语言 |
29.1. | This Agreement may be executed in several duplicates, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. For the avoidance of doubt, this Agreement is concluded both in Chinese version and English version. In the event of any discrepancy between the Chinese version and the English version, the English version shall prevail. |
29.1. | 本协议可签署多份副本,每一份副本均应被视为原件,且所有副本应共同构成同一文件。为避免疑义,本协议以中文和英文书就。若中文版本和英文版本之间存在不一致之处,应以英文版本为准。 |
30
In Witness whereof, the Parties have executed this Agreement by their duly authorized representatives.
兹证明,双方已由其正式授权代表签署本协议。
Amphastar Nanjing Pharmaceuticals, Inc. | | Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | ||
美药星(南京)制药有限公司 | | 南京汉欣医药科技有限公司 | ||
| | | | |
By/签署: | /s/Perky Qiu | | By/签署: | /s/Bob Bao |
| | | | |
Name/姓名: | Perky Qiu 邱银华 | | Name/姓名: | Bob Bao 鲍海涛 |
| | | | |
Title/职位: | General manager 总经理 | | Title/职位: | Vice General Manager 副总经理 |
| | | | |
Date/日期: | 2022-04-18 | | Date/日期: | 2022-04-18 |
31
APPENDIX A: PRODUCT AND CONTRACT PRICE
附录A:产品及合同价格
Product:
1. | ************** ******** |
2. | ************** ******** |
3. | ************** ******** |
4. | ************** ******** |
5. | ************** ******** |
6. | ************** ******** |
7. | ************** ******** |
Selling Price means, with respect to each Product, an amount equal to the sum of (i) the Direct Costs to manufacture such Product, plus (ii) **% of the amount of such Direct Costs plus any applicable taxes.
出售价格: 金额等于产品直接成本加上直接成本的**%以及所适用税款的总和。
“Direct Costs” means, with respect to a Product, the actual cost of raw materials, packaging components, overhead expense applied on a consistent basis with other products manufactured by ANP, and direct labor used to produce such Product. In no event will Direct Costs include expenses related to unutilized facility capacity, or allocations for corporate overheads.
直接成本:指乙方用于产品生产及相关的实际费用,包括:原材料,包装材料,管理及人工费用。任何情况下,直接成本都不包括未参与生产的设施费用,或公司内部管理费用。
32
APPENDIX B: SPECIFICATIONS
附录B:质量标准
Part of the product development works.
33